Safety of extending dosing intervals of denosumab in adults with solid cancer and bone metastasis: a review
{{output}}
Background: Denosumab is approved to be given every 4 weeks for the prevention of skeletal-related events in adults with solid cancer and bone metastasis. Research has suggested that it is safe to be given every 12 weeks, improvi... ...
